OMS721: Ph II data

Data from 2 patients with IgA nephropathy in an open-label, U.S. Phase II trial showed that OMS721 significantly reduced mean UACR to 525 mg/g at week 12 from 1,264 mg/g at baseline (p=0.011). Additio...